Transaction details
Arvinas NASDAQ:ARVN Chief Medical Officer Noah Berkowitz had 6,435 shares of the company’s common stock sold on March 18, 2026, at a per-share price of $11.1004. The transaction generated proceeds of $71,431 and, per the Form 4 filed with the Securities and Exchange Commission, reduced Berkowitz’s direct ownership in Arvinas to 202,503 shares.
The filing indicates the disposition was executed automatically by Arvinas, INC. to satisfy tax obligations arising from the vesting and settlement of restricted stock units that had been granted on March 18, 2024. The Form 4 specifically notes that the sale was not a discretionary trade by Berkowitz.
Market context and valuation note
At the time of the filing, the company’s shares were trading at $11.17. The stock has fallen 8.3% over the prior week but has gained 49% over the past six months. A valuation note included in the filing references InvestingPro analysis, which states Arvinas appears to be trading below its Fair Value estimate at current levels.
Clinical readouts and corporate developments
Arvinas recently reported Phase 1 clinical data for ARV-102, an investigational oral agent targeting leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease patients. The trial results showed reductions in LRRK2 levels in cerebrospinal fluid of approximately 50% or more across all dose levels by day 14.
On the corporate-development front, Arvinas and Pfizer have reached an agreement to jointly out-license vepdegestrant, with a PDUFA date set for June 2026 for the indication of ESR1-mutant metastatic breast cancer. Separately, Novartis has advanced Arvinas’s androgen receptor (AR) degrader luxdegalutamide into Phase II testing in combination with Pluvicto for metastatic castration-resistant prostate cancer.
Analyst reactions
Following the ARV-102 Phase 1 disclosure, several brokerages updated or reiterated their views: BTIG raised its price target to $16 while maintaining a Buy rating. Truist Securities reaffirmed a Hold rating with a $10.00 price target. Piper Sandler reiterated an Overweight rating and set a $20.00 price target, highlighting the Phase 1 data as validation of Arvinas’s oral PROTAC platform.
What the filing does - and does not - show
The Form 4 makes clear the share sale was an administrative, automatic action tied to tax settlement on vested RSUs and not a voluntary, discretionary sale by the executive. Beyond the mechanics of the transaction, the filing does not provide any commentary from Berkowitz or the company on strategic positioning or outlook.